Skip to content
DataLookout
Menu

NCT06586983

Decentralization of Hepatitis B Care in Sub-Saharan Africa: a Pilot Program in Ethiopia

StatusActive, Not Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 4 words Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Site details revised
    • Collaborators: details revised at 1 of 4 entries
    • Publications: details revised at 1 of 1 entry
  2. Notable Trial status: Active, Not Recruiting to Recruiting
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Death or liver decompensation
Timeframe: 3 years

Secondary (4)

Linkage to care
Loss to follow-up
Viral suppression
HIV incidence

Arms and interventions

Standard model ("treat only if")

HBsAg positive patients will be eligible for treatment of they fulfill one of the following criteria: i) Clinically diagnosed cirrhosis; or ii) APRI ≥0.5; or iii) Persistently elevated ALT \>40 U/L; or iv) Co-infection with HCV or HDV; or v) Family history of HCC/cirrhosis; or vi) Relevant co-morbidity

Inclusive model ("treat all except")

HBsAg positive patients will receive treatment, except if APRI ≤0.3 and no clinical signs/symptoms of cirrhosis and no risk factors for liver disease.

Test-and-treat model ("treat all")

All HBsAg positive patients will receive treatment.

Drugs: Tenofovir Disoproxil Fumarate

Sites

1 site in 1 country

  • Addis Ababa UniversityAddis Ababa, Addis Ababa, Ethiopia